Andrew P. Mazar, PhD
Chief Scientific Officer
is recognized internationally for his
work on the urokinase plasminogen activator (uPA) system and its role in tumor progression.
In addition to his
research work on the uPA system, Dr. Mazar
is a veteran of drug discovery having led various oncology drugs from basic research through phase II clinical trials.
Prior to Tactic Pharmaceuticals, Dr. Mazar was Chief Scientific Officer at Attenuon, where he led the development of three drug projects from discovery into human clinical trials.
He was also the Vice President of Biology at Ångstrom Pharmaceuticals, Inc., where he discovered the anti-angiogenic peptide Å6, which is currently being evaluated in phase II trials in oncology.
also discovered a novel uPA receptor-targeting peptide Å17, which was licensed to Diatide/Schering AG
Prior to Ångstrom, Dr. Mazar
spent over seven years at Abbott Laboratories
, where he
initiated two anti-angiogenesis pilot projects and was involved in the pre-clinicaldevelopment of two biologic agents that went through Phase III trials.
Dr. Mazar is also the co-inventor on twelve issued patents, forty pending patent applications, ninety-six full publications in refereed scientific journals, and eight book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of cancer.
Dr. Mazar received his Ph.D. in Biochemistry from the University of Illinois College of Medicine.